Sign up
Pharma Capital

Dynavax announces layoffs, floats selloff of immuno-oncology arm

The biopharmaceutical company is cutting 82 positions, roughly 37% of its workforce
placeholder
As part of the transition, CEO Eddie Gray announced he would step down

Dynavax Technologies Corporation (NASDAQ:DVAX) shares stumbled Friday after the company announced layoffs and teased plans to sell off its immuno-oncology portfolio late Thursday.

The biopharmaceutical company is cutting 82 positions, roughly 37% of its workforce. The move, coupled with the decision to explore strategic alternatives for its immuno-oncology portfolio, is an effort to prioritize the company’s approved Hepatitis B vaccine, its first commercial product. ‘

Its stock climbed more than 8% early in the Friday session but swiftly reversed course, dropping 7.6% to $5.86.

“Following a comprehensive analysis of our assets, strengths and opportunities, we have determined we should focus our resources on our approved vaccine, HEPLISAV-B,” CEO Eddie Gray said. “As a result, the board and management have made the difficult decision to reduce our workforce. We want to express our deepest appreciation to our employees for their invaluable contributions.”

As part of the transition, Gray announced he would step down. The company named David Noack and Ryan Spencer as interim co-presidents as the company searches for a new CEO. Novack and Spencer serve as vice presidents of operations and commercial, respectively.

Dynavex is a company focused on using the body’s innate immune responses to develop vaccines. It launched HEPLISAV-B in February 2018 after receiving approval from the US Food and Drug Administration.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

1551807154_andrew.jpg


Register here to be notified of future DVAX Company articles
View full DVAX profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.